Governance Ocugen, Inc.

OCGN

US67577C1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 15/01/2026 am IST			5-day change	1st Jan Change
1.880 ^USD	-1.57%		+22.08%	+39.26%

06/11	Ocugen, Inc., Q3 2025 Earnings Call, Nov 05, 2025
05/11	Ocugen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Executive Committee: Ocugen, Inc.

Manager

Positions heldSince

Shankar Musunuri

62 year

Chief Executive Officer	27/09/2019
Founder	01/01/2013

Arun Upadhyay

44 year

Chief Tech/Sci/R&D Officer

01/12/2020

Huma Qamar

42 year

Chief Tech/Sci/R&D Officer

18/03/2024

Jesse Simmers

Chief Tech/Sci/R&D Officer

Michael Breininger

44 year

Comptroller/Controller/Auditor

01/08/2023

Ramesh Ramachandran

57 year

Comptroller/Controller/Auditor	01/09/2024
Director of Finance/CFO	14/11/2024

Composition of the Board of Directors: Ocugen, Inc.

Director

CommitteesSince

Shankar Musunuri

62 year

Chairman

27/09/2019

Kirsten Castillo

53 year

Audit Committee	05/04/2020
Compensation Committee
Governance Committee Chair	06/10/2020
Nominating Committee Chair	06/10/2020

Uday Kompella

59 year

Compensation Committee	01/09/2013
Governance Committee	27/09/2019
Nominating Committee	27/09/2019

Junge Zhang

59 year

Governance Committee	01/09/2019
Nominating Committee	01/09/2019

Blaise Coleman

52 year

Director/Board Member

05/06/2025

C. Satish Chandran

70 year

Director/Board Member

05/06/2025

Latest Appointments: Ocugen, Inc.

21/25/21	Ocugen, Inc. Announces Appointments to Retina Scientific Advisory Board & Executive Leadership Team	CI
26/25/26	Ocugen, Inc. Announces Directorate Resignations	CI
16/24/16	Ocugen, Inc. Announces Executive Changes	CI
29/24/29	Ramesh Kumar Announces Not to Stand for Re-Election to the Board of Ocugen, Inc	CI
21/24/21	Ocugen, Inc. Announces Ramesh Kumar Will Not Stand for Re-Election as Director	CI
18/24/18	Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer	CI
16/24/16	Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board	CI

More news

Former Officers and Directors: Ocugen, Inc.

Insider

Positions held

SinceUntil

Michael Shine

Corporate Officer/Principal

10/06/2021

21/07/2025

Prabhavathi Fernandes

Director/Board Member	05/04/2020	05/06/2025
Independent Dir/Board Member	05/04/2020	05/06/2025

Marna Whittington

Director/Board Member	17/03/2022	05/06/2025
Independent Dir/Board Member	17/03/2022	05/06/2025

Ramesh Kumar

Comptroller/Controller/Auditor	-	15/09/2023
Director/Board Member	27/09/2019	28/06/2024
Independent Dir/Board Member	27/09/2019	28/06/2024

Robert J. Hopkins

Chief Tech/Sci/R&D Officer

01/09/2022

18/03/2024

Zara Gaudioso

Human Resources Officer

01/03/2021

01/10/2023

Quan Anh Vu

Comptroller/Controller/Auditor	10/03/2023	14/08/2023
Director of Finance/CFO	06/03/2023	14/08/2023
Corporate Officer/Principal	01/02/2023	06/03/2023

Jessica Crespo

Comptroller/Controller/Auditor	23/10/2019	10/03/2023
Director of Finance/CFO	18/03/2022	06/03/2023
Treasurer	23/10/2019	18/03/2022

J.P. Gabriel

Corporate Officer/Principal

01/01/2022

01/09/2022

Manish Potti

Director/Board Member	27/09/2019	07/06/2022
Independent Dir/Board Member	27/09/2019	07/06/2022

Kenneth Inchausti

Investor Relations Contact	21/06/2021	01/06/2022
Public Communications Contact	21/06/2021	01/06/2022

Sanjay Subramanian

Director of Finance/CFO	01/10/2019	18/03/2022
Investor Relations Contact	-	-
Corporate Secretary	01/06/2020	18/03/2022

Suha Halit Taspolatoglu

Director/Board Member	27/09/2019	10/12/2021
Independent Dir/Board Member	27/09/2019	10/12/2021

Rasappa Arumugham

Chief Tech/Sci/R&D Officer

01/03/2017

31/12/2020

Bruce D. Forrest

Chief Tech/Sci/R&D Officer

01/12/2020

Daniel M. Jorgensen

Chief Tech/Sci/R&D Officer

01/04/2017

15/07/2020

Kelly Beck

Chief Administrative Officer	01/07/2017	01/06/2020
Investor Relations Contact	01/07/2017	01/06/2020

Frank Leo

Director/Board Member	27/09/2019	03/04/2020
Independent Dir/Board Member	27/09/2019	03/04/2020

Susan Drexler

Director of Finance/CFO

01/04/2018

01/06/2019

Nirdosh Jagota

Compliance Officer	-	-
General Counsel	-	-

Mohamed Genead

Chief Tech/Sci/R&D Officer

Andrew Walsh

Corporate Officer/Principal	-	-
Treasurer	-	-

Age distribution of managers

Parity Men Women

Male	11
Female	2

Of which Executive Committee

Male	6
Female	0

Of which Directors

Male	5
Female	1

Revisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.

Employees

Sector

Biotechnology & Medical Research

Calendar

07:00pm - OCU410 Phase 2 Trial Results Call

More about the company